Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Categories

All Quarterly Result Economy Mutual Fund Business Company Market Budget IPO

Dr. Reddy’s API plant completes U.S. FDA inspection in Srikakulam facility

Jul 20, 2023

By: BlinkX Research Team

Dr Reddy's Laboratories Ltd. said in the regulatory filing on Wednesday that the US FDA (Food and Drug Administration) has successfully completed both the pre-approval inspection and a routine inspection of good manufacturing practices at the API manufacturing facility in Srikakulam, Andhra Pradesh, with no observations.

The facility for active pharmaceutical ingredients (APIs) was examined between July 10 and July 19, 2023.

According to the company's filing with the exchange, it closed with no observations and was classified as No Action Indicated (NAI).

Reacting to this news, the share price of the company gained by Rs 148.6 or 2.8% at Rs 5,370.2 apiece on BSE, surpassing an earlier 52-week high of Rs 5,272.4 apiece hit on July 7.

Source: Media Reports